申请人:TEIJIN LIMITED
公开号:EP1535909A2
公开(公告)日:2005-06-01
A compound represented by general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. Since these compounds inhibit the action of chemokines such as MIP-1α and/or MCP-1 on target cells, they may be useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.
通式(I)代表的化合物、其药学上可接受的酸加成盐或其药学上可接受的 C1-C6 烷基加成盐及其医学应用。由于这些化合物可抑制 MIP-1α 和/或 MCP-1 等趋化因子对靶细胞的作用,因此可用作动脉粥样硬化、类风湿性关节炎等血液中单核细胞和淋巴细胞渗入组织的疾病的治疗药物和/或预防药物。